<DOC>
	<DOCNO>NCT02344186</DOCNO>
	<brief_summary>The main objective study test hypothesis treatment Liraglutide decrease ER stress adipose tissue obese patient type 2 diabetes . Experimental Approach : The investigator use prospective , single blind , placebo control study design study 12 obese patient type 2 diabetes mellitus ( T2DM ) . 6 patient first receive Liraglutide 24 week follow placebo 12 week . The 6 patient first receive placebo 12 week follow Liraglutide 24 week . Measurements : The investigator determine glycemic control ( HbA1c ) , body composition ( bioelectric impedance analysis ) , insulin sensitivity ( hyperinsulinemic-euglycemic clamp ) , insulin secretion ( oral glucose tolerance test ) , energy balance ( calorie vs. calorie ) , plasma lipid level obtain subcutaneous fat biopsy determine ER stress response marker placebo Liraglutide treatment .</brief_summary>
	<brief_title>Effects Liraglutide ER Stress Obese Patients With Type 2 Diabetes</brief_title>
	<detailed_description>This prospective , single-blind , placebo-controlled study crossover design . Visit Procedures : After 1 month run-in period change medication , physical activity diet , patient randomly divide 2 group 6 patient . Subjects 50:50 chance randomize either group 1 group 2 . In Group 1 , ( n=6 ) , liraglutide start first 0.6 mg/d 1 week , increase 1.2 mg/d week 2 week 12 , follow 1.8 mg/d week 12 week 24 . Group 1 patient switch liraglutide placebo injection another 12 week . For subject Group 1 placebo period ( week 24 36 washout period . Group 2 patient ( n=6 ) start placebo 12 week switch liraglutide next 24 week ( 0.6 mg/d 1 week , 1.2 mg/d 11 week 1.8 mg/d 12 week ) . Assessment Efficacy Outpatient visit : During entire study , patient ( Groups 1 2 ) perform home glucose monitor 7 times/day ( pre ~ 2 h post breakfast , lunch dinner bedtime ) see Temple University Hospital outpatient 4 week interval . One week first , second third final inpatient visit , patient undergo 75 , gram 2-hour oral glucose tolerance test . Inpatient visit : All patient ( Groups 1 2 ) study Clinical Research Center ( CRC ) Temple University Hospital morning overnight fast , end run-in period ( Week 0 ) Weeks 12 , 24 36 . All study patient admit CRC even study discharge PM follow day . During inpatient visit , follow procedure perform . 1 . At baseline week 12 36 , subcutaneous fat biopsy obtain lateral aspect one thigh surgeon describe ( 8 ) determination ER stress marker . In brief , skin clean betadine anesthetized 1 % lidocaine without epinephrine field block pattern ( 2 X 3 ) . ( We find injection lidocaine close biopsy site interfered measurement acetyl-CoA ) . After incision ( ~ 1 . ) make skin , ~ 300 mg fat mobilize excise . The fat drop immediately isopentane , keep freeze point ( -160°C ) liquid nitrogen . The frozen fat store -70° . To screen change unfold protein response ( UPR ) gene , first perform UPR PCR microarray ( SA Biosciences , Frederick , MD ) use pool fat biopsy extract . This array profile expression 84 key gene recognize respond misfolded protein accumulation ER . Significant change ( &gt; 1.5 fold compare post vs. pre drug biopsy ) confirm real time RT-PCR UPR mRNAs . Thus , mRNAs identify UPR marker ( instance , GRP78 , XBP-1s , ATF4 , ATF6 , PDI , calreticulin , calnexin ) measure real time RT-PCR triplicate normalize 18 β-actin mRNAs express arbitrary unit . The respective protein analyze Western blot . 2 . Glycemic control assess 1. measurement HbA1c 2. patient home glucose monitoring record 3 . Determination insulin resistance determine ( euglycemic-hyperinsulinemic clamping use stable isotope determination peripheral ( GRd ) hepatic ( GRa ) insulin action describe ( 18 ) . 4. . Determination energy balance , calculated change fat mass ( bioelectric impedance analysis ) plus total energy expenditure ( determined indirect calorimetry doubly label water method ) ( 17 ) . 5 . Postabsorptive blood sample obtain determination plasma lipid ( total cholesterol , LDL , HDL triglycerides ) . 6 . Assessment change insulin secretion determine Oral Glucose Tolerance Testing .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Patients establish type 2 diabetes , BMI 2735 , Age 1875 year , HbA1c 710 % , patient treat exercise , diet , metformin and/or alpha glucosidase inhibitor ( ½ maximal dose ) pioglitazone ( 30 mg/d ) , ability provide inform consent trialrelated activity . Patients pancreatitis history pancreatitis , patient HbA1c &lt; 7 % &gt; 10 % , type 2 diabetic patient treated insulin , sulfonylurea , meglitinides , DPP4 inhibitor , GLP1 agonists corticosteroid , patient hypoglycemia unawareness impaired liver function ( ≥ 2.5 time upper normal limit ) , know suspect allergy liraglutide contraindication liraglutide ( specified product prescribe information ) , pregnancy , breastfeed intention become pregnant use adequate contraceptive measure , patient personal family history medullary thyroid cancer patient Multiple Endocrine Neoplasia type 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>diabetes , endoplasmic reticulum stress , obesity , GLP1 analog</keyword>
</DOC>